Acute Coronary Syndrome Management with Aspirin and P2Y12 Inhibitors

Introduction to Aspirin and Clopidogrel Therapy

The American Heart Association recommends an initial oral loading dose of aspirin (162-325 mg) followed by daily low-dose aspirin, along with a loading dose of a P2Y12 inhibitor such as clopidogrel (300-600 mg), to reduce death and major adverse cardiovascular events in patients with acute coronary syndrome (ACS) 1, 2

Aspirin loading (162-325 mg) should be administered to all patients with ACS without absolute contraindications as soon as possible on presentation, regardless of final management strategy (invasive or non-invasive) 1, 2
Non-enteric coated aspirin should be chewed when possible to achieve faster onset of antiplatelet action 1
Loading dose should be administered even for patients already on aspirin therapy 1
Following loading, maintenance therapy with low-dose aspirin (75-100 mg daily) is recommended for long-term use 1

Clopidogrel loading (300 or 600 mg) is indicated in patients with non-ST-segment elevation ACS (NSTE-ACS) or ST-segment elevation myocardial infarction (STEMI) without fibrinolytic therapy 1, 2
For STEMI with fibrinolytic therapy, a reduced loading dose of 300 mg is indicated for patients ≤75 years old, while patients >75 years should start with 75 mg 1

Antiplatelet loading should be initiated as early as possible in the course of ACS 1, 2
With a 300 mg loading dose of clopidogrel, antiplatelet effects appear within 90 minutes, and after 6 hours, the antithrombotic effects are equivalent to those achieved after 10 days of therapy 6, 4
In patients with STEMI managed with primary PCI, prasugrel or ticagrelor should be administered in preference to clopidogrel to reduce major adverse cardiovascular events and stent thrombosis 1

Clopidogrel should be withheld for at least 5 days before elective coronary artery bypass graft surgery 3, 4
For patients on P2Y12 inhibitors who need non-emergent cardiac surgery, postponing surgery is recommended for at least 3 days after discontinuation of ticagrelor, at least 5 days after clopidogrel, and at least 7 days after prasugrel 8
For patients at high bleeding risk, consider using proton pump inhibitors in combination with dual antiplatelet therapy to reduce bleeding risk, as recommended by the European Society of Cardiology 9